title: Discovery and characterization of antibody variants using mass spectrometry-based comparative analysis for biosimilar candidates of monoclonal antibody drugs.
abstract: Liquid chromatography mass spectrometry (LC-MS) is the most commonly used technique for the characterization of antibody variants. MAb-X and mAb-Y are two approved IgG1 subtype monoclonal antibody drugs recombinantly produced in Chinese hamster ovary (CHO) cells. We report here that two unexpected and rare antibody variants have been discovered during cell culture process development of biosimilars for these two approved drugs through intact mass analysis. We then used comprehensive mass spectrometry-based comparative analysis including reduced light, heavy chains, and domain-specific mass as well as peptide mapping analysis to fully characterize the observed antibody variants. The "middle-up" mass comparative analysis demonstrated that the antibody variant from mAb-X biosimilar candidate was caused by mass variation of antibody crystalline fragment (Fc), whereas a different variant with mass variation in antibody antigen-binding fragment (Fab) from mAb-Y biosimilar candidate was identified. Endoproteinase Lys-C digested peptide mapping and tandem mass spectrometry analysis further revealed that a leucine to glutamine change in N-terminal 402 site of heavy chain was responsible for the generation of mAb-X antibody variant. Lys-C and trypsin coupled non-reduced and reduced peptide mapping comparative analysis showed that the formation of the light-heavy interchain trisulfide bond resulted in the mAb-Y antibody variant. These two cases confirmed that mass spectrometry-based comparative analysis plays a critical role for the characterization of monoclonal antibody variants, and biosimilar developers should start with a comprehensive structural assessment and comparative analysis to decrease the risk of the process development for biosimilars.
authors.affiliation: Sunshine Lake Pharma Co., Ltd, Dongguan 523867, China. Electronic address: liwenhua@hecpharm.com.
authors.forename: Wenhua
authors.initials: W
authors.lastname: Li
authors.affiliation: Sunshine Lake Pharma Co., Ltd, Dongguan 523867, China.
authors.forename: Bin
authors.initials: B
authors.lastname: Yang
authors.affiliation: Sunshine Lake Pharma Co., Ltd, Dongguan 523867, China.
authors.forename: Dongmei
authors.initials: D
authors.lastname: Zhou
authors.affiliation: Sunshine Lake Pharma Co., Ltd, Dongguan 523867, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Xu
authors.affiliation: Sunshine Lake Pharma Co., Ltd, Dongguan 523867, China.
authors.forename: Zhi
authors.initials: Z
authors.lastname: Ke
authors.affiliation: Sunshine Lake Pharma Co., Ltd, Dongguan 523867, China. Electronic address: wenchensuen@hecpharm.com.
authors.forename: Wen-Chen
authors.initials: WC
authors.lastname: Suen
mesh_terms: D000911:Antibodies, Monoclonal / Q000032:analysis* / Q000737:chemistry*; D059451:Biosimilar Pharmaceuticals / Q000032:analysis* / Q000737:chemistry*; D002853:Chromatography, Liquid / Q000379:methods; D013058:Mass Spectrometry / Q000379:methods; D020539:Sequence Analysis, Protein / Q000379:methods*
chemical_list: D000911:Antibodies, Monoclonal; D059451:Biosimilar Pharmaceuticals
keywords: Antibody variants; Biosimilar; Comparative analysis; Mass spectrometry; Monoclonal antibody; Process development